PEB - Pacific Edge Ltd

[winner69]

That’s not a 12 month price target, it’s a present day base case valuation of Pacific Edge at $1.16 and a conservative one by Edison’s own explanation. That’s +40% from here for those that want it.

Watch for further ongoing incremental upgrades over time as that conservatism along with that of the other analysts relaxes.

Sheer nature of their DCF valuation is $1.16 now with 12.5% pa (their discount rate) gains going forward eh MAC.

A 12 month target would be $1.16 plus 12.5% giving $1.31 - even better eh

[BFG]

Sheer nature of their DCF valuation is $1.16 now with 12.5% pa (their discount rate) gains going forward eh MAC.

A 12 month target would be $1.16 plus 12.5% giving $1.31 - even better eh

Unfortunately, the market is always right, even when it's wrong eh?

For those who don't believe in efficient market theory and subscribe to DCF, this is a great op to buy in before CMS coverage. Even the charts stack up to an uptrend.

Starting to wonder...

[MAC]

Sheer nature of their DCF valuation is $1.16 now with 12.5% pa (their discount rate) gains going forward eh MAC.

A 12 month target would be $1.16 plus 12.5% giving $1.31 - even better eh

Well yes the big casflows will be a year closer in a year’s time sure, but I would offer the following points.

There is also a lot of room for upgrades arising from a relaxation of conservatism, and also when they include new products ahead of their release into the market.

“We include sales for Cxbladder Detect and Cxbladder Triage, conservatively excluding additional pipeline products in our forecasts”

At some point in 2015 Edison will need to include the new product Cxbladder(prognosis) into the valuation, presently undergoing clinical trials and due to be launched in 2015.

Similarly, there are the Cxcolorectal and the Melanoma prospects which they also don’t yet include within their valuation and at some point will also need to do so.

They have also yet to value the European and Asian prospective markets.

“We also forecast sales into the US, New Zealand and Australia only and do not factor in potential added value for the company’s technology”

And then there is the matter of penetration and price point sensitivity analysis giving rise to their valuation range of $0.42 to $3.57.

“Our base case is on the conservative side in both regards, therefore we expect significant upside potential on our forecasts if Pacific Edge’s performance exceeds our cautious expectations.”

My feel is that they will keep stepping up forecasts and will probably fully value Pacific Edge within that range at some point, possibly when Pacific Edge become profitable at FY16.

But then, of course that range may well be higher by that time as they probably will have included at least some new products and markets.

[Baddarcy]

Saw this this morning, its treatment rather than detection.

http://www.nzherald.co.nz/business/n...ectid=11376633

[BFG]

For another very interesting Sorehead sucker scheme dreamed up to fund his lifestyle with 0.0005 cent shares, see TRU on the NZAX

There, fixed for you

[robbo24]

There, fixed for you

Chortle, ho ho ho.

[BFG]

Pietrade, your copy and paste advertising for TRU has been reported.

DYOR

[skid]

That’s not a 12 month price target, it’s a present day base case valuation of Pacific Edge at $1.16 and a conservative one by Edison’s own explanation. That’s +40% from here for those that want it.

Watch for further ongoing incremental upgrades over time as that conservatism along with that of the other analysts relaxes.

I was going by the last paragraph of the report we discussed--For Bar said they see PEB on a 12 month target price of $1.25 (sorry my 1.15 was a misprint)

[skid]

Saw this this morning, its treatment rather than detection.

http://www.nzherald.co.nz/business/n...ectid=11376633

One can see why a sexy product like that (with that sort of potential) would be bought.

[skid]

There, fixed for you

Be nice Moosie --its the Chrismas season